FR23C1041I2 - Alpha-galactosidase stabilise et ses utilisations - Google Patents

Alpha-galactosidase stabilise et ses utilisations

Info

Publication number
FR23C1041I2
FR23C1041I2 FR23C1041C FR23C1041C FR23C1041I2 FR 23C1041 I2 FR23C1041 I2 FR 23C1041I2 FR 23C1041 C FR23C1041 C FR 23C1041C FR 23C1041 C FR23C1041 C FR 23C1041C FR 23C1041 I2 FR23C1041 I2 FR 23C1041I2
Authority
FR
France
Prior art keywords
galactosidase
stabilized alpha
stabilized
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1041C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protalix Ltd
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/fr
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of FR23C1041I1 publication Critical patent/FR23C1041I1/fr
Application granted granted Critical
Publication of FR23C1041I2 publication Critical patent/FR23C1041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
FR23C1041C 2010-03-02 2023-11-02 Alpha-galactosidase stabilise et ses utilisations Active FR23C1041I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (fr) 2009-11-17 2010-11-17 Alpha galactosidase alcaline pour le traitement de la maladie de fabry
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20
EP11712340.6A EP2542675B1 (fr) 2010-03-02 2011-03-02 Alpha-galactosidase stabilisée et ses applications

Publications (2)

Publication Number Publication Date
FR23C1041I1 FR23C1041I1 (fr) 2023-12-29
FR23C1041I2 true FR23C1041I2 (fr) 2024-08-02

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1041C Active FR23C1041I2 (fr) 2010-03-02 2023-11-02 Alpha-galactosidase stabilise et ses utilisations

Country Status (23)

Country Link
EP (3) EP2865751B1 (fr)
JP (2) JP5758920B2 (fr)
KR (1) KR101928403B1 (fr)
CN (1) CN102933707B (fr)
AU (1) AU2011222452B2 (fr)
BR (2) BR122014021216A2 (fr)
CA (1) CA2791461C (fr)
DK (1) DK2865751T3 (fr)
ES (2) ES2606532T3 (fr)
FI (1) FIC20230032I1 (fr)
FR (1) FR23C1041I2 (fr)
HR (1) HRP20200428T1 (fr)
HU (2) HUE030959T2 (fr)
IL (2) IL221741A (fr)
IN (1) IN2012MN02262A (fr)
NL (1) NL301249I2 (fr)
NO (1) NO2023041I1 (fr)
NZ (2) NZ623294A (fr)
PL (1) PL2865751T3 (fr)
SG (2) SG183558A1 (fr)
SI (1) SI2865751T1 (fr)
WO (1) WO2011107990A1 (fr)
ZA (1) ZA201206725B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
SI2865751T1 (sl) * 2010-03-02 2017-01-31 Protalix Ltd. Stabilizirana alfa-galaktozidaza in njene uporabe
KR101883803B1 (ko) * 2011-01-20 2018-07-31 프로탈릭스 리미티드 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
LT3237621T (lt) * 2014-12-22 2023-09-25 Codexis, Inc. Žmogaus alfa-galaktozidazės variantai
WO2016116966A1 (fr) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes
WO2016146760A1 (fr) 2015-03-17 2016-09-22 Greenovation Biotech Gmbh Protéines lysosomales glycosylées, procédé de production et utilisations
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2018127920A1 (fr) * 2017-01-05 2018-07-12 Protalix Ltd. Régime thérapeutique pour le traitement de la maladie de fabry à l'aide d'une alpha-galactosidase stabilisée
US11517613B2 (en) * 2017-06-07 2022-12-06 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
AU2019403323B2 (en) 2018-12-20 2026-02-26 Codexis, Inc. Human alpha-galactosidase variants
CA3173294A1 (fr) * 2020-02-28 2021-09-02 Codexis, Inc. Variants d'alpha-galactosidase humaine
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (fr) 1991-10-03 1993-04-04 Guy Ampleman Polymere de glycidylazide
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DE69839563D1 (de) * 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
DE60022336T2 (de) * 1999-04-02 2006-06-22 Ajinomoto Co., Inc. Vefahren zur herstellung von peptiduntereinheiten aus polymer-proteinen
DK1523548T3 (da) 2002-05-15 2010-05-10 Agricultural Res Org Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
EP1877099B1 (fr) * 2005-04-06 2012-09-19 Genzyme Corporation Conjugués thérapeutiques comprenant une enzyme lysosomale, l'acide polysialique et un agent de ciblage
BRPI0618583A2 (pt) * 2005-11-18 2011-09-06 Tokyo Metropolitan Org Med Res enzima altamente funcional tendo especifidade ao substrato modificada
WO2008075957A1 (fr) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Traitement de la maladie de fabry
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (fr) * 2007-02-09 2008-08-13 Scil proteins GmbH Conjugué multimère
CA2696699A1 (fr) 2007-08-20 2009-02-26 Protalix Ltd. Conjugues de proteines contenant un saccharide et leurs utilisations
SI2865751T1 (sl) * 2010-03-02 2017-01-31 Protalix Ltd. Stabilizirana alfa-galaktozidaza in njene uporabe

Also Published As

Publication number Publication date
HRP20200428T1 (hr) 2020-06-12
CN102933707B (zh) 2015-09-30
WO2011107990A1 (fr) 2011-09-09
JP5758920B2 (ja) 2015-08-05
FR23C1041I1 (fr) 2023-12-29
SG183558A1 (en) 2012-10-30
BR112012022029B1 (pt) 2022-10-11
HUS2300038I1 (hu) 2023-11-28
DK2865751T3 (en) 2017-01-09
CA2791461A1 (fr) 2011-09-09
KR20130056216A (ko) 2013-05-29
RU2012141651A (ru) 2014-04-10
NL301249I2 (nl) 2023-12-14
ES2708843T3 (es) 2019-04-11
JP2013520986A (ja) 2013-06-10
SI2865751T1 (sl) 2017-01-31
BR112012022029A2 (pt) 2021-05-18
FIC20230032I1 (fi) 2023-11-02
IL253249A (en) 2019-08-29
SG10201502609QA (en) 2015-05-28
BR122014021216A2 (pt) 2021-06-01
JP2014237694A (ja) 2014-12-18
HUE030959T2 (en) 2017-06-28
ES2606532T3 (es) 2017-03-24
CN102933707A (zh) 2013-02-13
IL253249B (en) 2020-08-31
PL2865751T3 (pl) 2017-03-31
HK1180720A1 (en) 2013-10-25
JP5871999B2 (ja) 2016-03-01
EP2865751B1 (fr) 2016-09-14
IN2012MN02262A (fr) 2015-06-12
AU2011222452A1 (en) 2012-09-27
EP3088514A1 (fr) 2016-11-02
NZ623294A (en) 2015-10-30
IL221741A (en) 2017-07-31
NO2023041I1 (no) 2023-11-01
EP3088514B1 (fr) 2018-11-28
EP2865751A1 (fr) 2015-04-29
CA2791461C (fr) 2019-10-22
NL301249I1 (fr) 2023-11-08
RU2604795C2 (ru) 2016-12-10
ZA201206725B (en) 2013-06-26
AU2011222452B2 (en) 2015-09-03
NZ602317A (en) 2014-04-30
EP2542675A1 (fr) 2013-01-09
EP2542675B1 (fr) 2014-12-17
KR101928403B1 (ko) 2018-12-14

Similar Documents

Publication Publication Date Title
FR23C1041I2 (fr) Alpha-galactosidase stabilise et ses utilisations
EP2640854A4 (fr) ARNnc ET UTILISATIONS DE CELUI-CI
EP2701730A4 (fr) Mfg-e8 et ses utilisations
EP2593463A4 (fr) Formulations de rifaximine et utilisations correspondantes
EP2605789A4 (fr) Polypeptides de relaxine modifiés et leurs utilisations
EP2646446A4 (fr) Inhibiteurs de bromodomaines et leurs utilisations
EP2638052A4 (fr) Inhibiteurs sélectifs de glycosidase et utilisations de ceux-ci
EP2638009A4 (fr) Inhibiteurs fluorés de hdac et leurs utilisations
BR112012027159A2 (pt) estrutura e método
EP2721061A4 (fr) Peptides maml variants stabilisés et leurs utilisations
DK2613884T3 (da) Findelingsindretning
EP2774914A4 (fr) Dérivé de n-benzylaniline et ses utilisations
EP2471799A4 (fr) Complexe de terre rare et ses utilisations
EP2576776A4 (fr) Bêta-lactamases modifiées et procédés et utilisations associés
EP2608785A4 (fr) Lipomacrocycles et leurs utilisations
EP2683360A4 (fr) Apeline pégylée et ses utilisations
EP2483292A4 (fr) Polypeptides lovd variants et leurs utilisations
EP2582836A4 (fr) Modulateurs de prpk-tprkb et leurs utilisations
EP2637503A4 (fr) Inhibiteurs sélectifs de la glycosidase et utilisations de ceux-ci
BR112013009579A2 (pt) método e comprimido
EP2699272A4 (fr) Agents de contraste et utilisations associées
EP2627324A4 (fr) Benzamides substitués et leurs utilisations
EP2556055A4 (fr) Inhibiteurs de ship et leurs utilisations
FI20105938L (fi) Valojohde ja sen valmistus
FR2964937B1 (fr) Triporteur et direction de triporteur